- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial
This study looks at how well a medicine called ocrelizumab works and if it's safe for people with multiple sclerosis (MS). It's for patients who have already been in similar studies with the same medicine.
Hungary · Norway · Croatia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab in Patients with Multiple Sclerosis
This study is looking at a new way to give a medicine called Ocrevus to people with Multiple Sclerosis (MS). Instead of an IV drip, it might be given as a shot under the skin. We want to see if it works just as well and is safe.
Spain · Czechia · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis
This study is looking at a new treatment called glofitamab for multiple sclerosis (MS). Researchers want to see if it's safe, how well the body handles it, and how it works after patients have taken another medicine called ocrelizumab.
Croatia · Czechia - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis
This study is testing a new injection of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's looking at whether different doses are safe, how the body handles the medicine, and what effects it has. It's a very early-stage study.
Belgium · France · Czechia